Primary Site >> Colorectal Cancer
Gene >> CYP2C19
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. PMID: 12419832 |
Ref: A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. PMID: 16006997 |
Ref: CYP2C19 polymorphisms in patients with gastric and colorectal carcinoma. PMID: 17290075 |
Ref: Identification of NR1I2 genetic variation using resequencing. PMID: 17404718 |
Ref: Drug interactions between chemotherapeutic regimens and antiepileptics. PMID: 18803983 |
Ref: Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk. PMID: 21317201 Ref: Modification of menopausal hormone therapy-associated colorectal cancer risk by polymorphisms in sex steroid signaling, metabolism and transport related genes. PMID: 21490239 |
Ref: Cytotoxic and potent CYP1 inhibitors from the marine algae Cymopolia barbata. PMID: 22686946 |
Ref: Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors. PMID: 23833302 |
Ref: Genetic variations in the xenobiotic-metabolizing enzymes CYP1A1, CYP1A2, CYP2C9, CYP2C19 and susceptibility to colorectal cancer among Turkish people. PMID: 24527758 |
Ref: Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases. PMID: 26233904 |
Ref: Prediction of Early Recurrence After Curative Resection of Colorectal Liver Metastasis and Subsequent S-1 Chemotherapy. PMID: 27127120 |
Ref: Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). PMID: 28817838 |